The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Association Between Disease-Modifying Antirheumatic Drugs and Diabetes Risk in Patients With Rheumatoid Arthritis and Psoriasis
Abstract
CONTEXT: Rheumatoid arthritis (RA) and psoriasis have been linked with insulin resistance and diabetes mellitus (DM). Prior investigations suggest that systemic immunosuppressive drugs may improve insulin resistance and reduce the risk of DM. OBJECTIVE: To compare the risk of newly recorded DM among participants diagnosed with RA or psoriasis based on use of a variety of disease-modifying antirheumatic drugs (DMARDs). DESIGN, SETTING, AND PARTICIPANTS: A retrospective cohort study among 121,280 patients with a diagnosis of either RA or psoriasis on at least 2 visits. The analyses were conducted in the context of 2 large health insurance programs, 1 in Canada and 1 in the United States, using administrative data. The mean follow-up was 5.8 months and began with the first prescription for a DMARD after study eligibility was met. Drug regimens were categorized into 4 mutually exclusive groups: (1) tumor necrosis factor (TNF) inhibitors with or without other DMARDs; (2) methotrexate without TNF inhibitors or hydroxychloroquine; (3) hydroxychloroquine without TNF inhibitors or methotrexate; or (4) other nonbiologic DMARDs without TNF inhibitors, methotrexate, or hydroxychloroquine (reference exposure). MAIN OUTCOME MEASURE: Newly recorded DM as evidenced by a new diagnosis of DM with use of a DM-specific medication. RESULTS: The study cohort consisted of 13,905 participants with 22,493 treatment episodes starting 1 of the categories of DMARD regimens between January 1996 and June 2008. New diabetes cases and respective incidence rates per 1000 person-years were: other nonbiologic DMARDs (55 cases among 3993 treatment episodes; rate, 50.2; 95% confidence interval [CI], 47.3-53.2); TNF inhibitors (80 cases among 4623 treatment episodes; rate, 19.7; 95% CI, 19.1-20.3); methotrexate (82 cases among 8195 treatment episodes; rate, 23.8; 95% CI, 23.0-24.6); and hydroxychloroquine (50 cases among 5682 treatment episodes; rate, 22.2; 95% CI, 21.3-23.1). The multivariate adjusted hazard ratios for DM were 0.62 (95% CI, 0.42-0.91) for TNF inhibitors, 0.77 (95% CI, 0.53-1.13) for methotrexate, and 0.54 (95% CI, 0.36-0.80) for hydroxychloroquine compared with other nonbiologic DMARDS. CONCLUSION: Among patients with RA or psoriasis, the adjusted risk of DM was lower for individuals starting a TNF inhibitor or hydroxychloroquine compared with initiation of other nonbiologic DMARDs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases
DEYO, R. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90133-8 · Cited by 10,452
Inflammation and Atherosclerosis
Libby, P., Ridker, P. M., & Maseri, A. (2002) · Circulation · doi:10.1161/hc0902.104353 · Cited by 7,724
C-Reactive Protein, Interleukin 6, and Risk of Developing Type 2 Diabetes Mellitus
Pradhan, A. D. (2001) · JAMA · doi:10.1001/jama.286.3.327 · Cited by 4,433
Inflammation, stress, and diabetes
Wellen, K. E., & Hotamisligil, G. S. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25102 · Cited by 4,143
Risk of myocardial infarction in patients with psoriasis
Gelfand, J. M., Neimann, A. L., Shin, D. B., Wang, X., Margolis, D. J., & Troxel, A. B. (2006) · JAMA · doi:10.1001/jama.296.14.1735 · Cited by 1,899
Interleukin-1-receptor antagonist in type 2 diabetes mellitus
Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065213 · Cited by 1,798
Romano, P. S., Roos, L. L., & Jollis, J. G. (1993) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(93)90103-8 · Cited by 1,717
Evaluating medication effects outside of clinical trials: new-user designs
Ray, W. A. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg231 · Cited by 1,646
Checking the Cox model with cumulative sums of martingale-based residuals
LIN, D. Y., WEI, L. J., & YING, Z. (1993) · Biometrika · doi:10.1093/biomet/80.3.557 · Cited by 1,432
A review of uses of health care utilization databases for epidemiologic research on therapeutics
Schneeweiss, S., & Avorn, J. (2005) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2004.10.012 · Cited by 1,277
Cardiovascular Morbidity and Mortality in Women Diagnosed With Rheumatoid Arthritis
Solomon, D. H., Karlson, E. W., Rimm, E. B., Cannuscio, C. C., Mandl, L. A., Manson, J. E., Stampfer, M. J., & Curhan, G. C. (2003) · Circulation · doi:10.1161/01.cir.0000054612.26458.b2 · Cited by 1,246
Self-citationFesta, A., D’Agostino, R., Tracy, R. P., & Haffner, S. M. (2002) · Diabetes · doi:10.2337/diabetes.51.4.1131 · Cited by 1,057
Explaining How “High-Grade” Systemic Inflammation Accelerates Vascular Risk in Rheumatoid Arthritis
Sattar, N., McCarey, D. W., Capell, H., & McInnes, I. B. (2003) · Circulation · doi:10.1161/01.cir.0000099844.31524.05 · Cited by 942
Cardiovascular death in rheumatoid arthritis: A population‐based study
Maradit‐Kremers, H., Nicola, P. J., Crowson, C. S., Ballman, K. V., & Gabriel, S. E. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20878 · Cited by 934
Han, C., Robinson, D., Hackett, M., Paramore, L. C., Fraeman, K. H., & BALA, M. M. (2006) · PubMed · Cited by 721
Accuracy of ICD-9-CM Codes for Identifying Cardiovascular and Stroke Risk Factors
Birman-Deych, E., Waterman, A. D., Yan, Y., Nilasena, D. S., Radford, M. J., & Gage, B. F. (2005) · Medical Care · doi:10.1097/01.mlr.0000160417.39497.a9 · Cited by 719
Cardiovascular Morbidity and Mortality in Rheumatoid Arthritis
Gabriel, S. E. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.06.011 · Cited by 315
González-Gay, M. Á., Matias, J. M. D., González‐Juanatey, C., Garcı́a-Porrúa, C., Sanchez-Andrade, A., Martin, J. J., & Llorca, J. (2006) · PubMed · Cited by 313
Solomon, D. H., Kremer, J., Curtis, J. R., Hochberg, M. C., Reed, G., Tsao, P., Farkouh, M. E., Setoguchi, S., & Greenberg, J. D. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.122226 · Cited by 297
Self-citationHydroxychloroquine and Risk of Diabetes in Patients With Rheumatoid Arthritis
Wasko, M. C. M., Hubert, H. B., Lingala, V. B., Elliott, J. R., Luggen, M. E., Fries, J. F., & Ward, M. M. (2007) · JAMA · doi:10.1001/jama.298.2.187 · Cited by 291
A basic study design for expedited safety signal evaluation based on electronic healthcare data
Schneeweiss, S. (2010) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1926 · Cited by 255
Kiortsis, D. N., Mavridis, A. K., Vasakos, S., Nikas, S. N., & Drosos, A. A. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.026534 · Cited by 254
Psoriasis and the Risk of Diabetes and Hypertension: A Prospective Study of US Female Nurses
Qureshi, A. A., Choi, H. K., Setty, A. R., & Curhan, G. C. (2009) · Archives of Dermatology · doi:10.1001/archdermatol.2009.48 · Cited by 250
Gelfand, J. M., Berlin, J., Van Voorhees, A., & Margolis, D. J. (2003) · Archives of Dermatology · doi:10.1001/archderm.139.11.1425 · Cited by 249
del Rincón, I., Freeman, G. L., Haas, R. W., O'Leary, D. H., & Escalante, A. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21397 · Cited by 244
Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis and psoriasis
Solomon, D. H., Love, T. J., Canning, C., & Schneeweiss, S. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.125476 · Cited by 211
Self-citationLiu, S. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.15.1676 · Cited by 198
Developments in Post-marketing Comparative Effectiveness Research
Schneeweiss, S. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100249 · Cited by 197
Tam, L.-S., Tomlinson, B., Chu, T. T., Li, T. K., & Li, E. K. (2007) · Clinical Rheumatology · doi:10.1007/s10067-007-0539-8 · Cited by 197
Inflammation and Atherosclerosis
Jialal, I., & Devaraj, S. (2001) · Pathology Patterns Reviews · doi:10.1309/j63v-5lth-wyfc-vdr5 · Cited by 192
Hemostatic Markers of Endothelial Dysfunction and Risk of Incident Type 2 Diabetes
Meigs, J. B., O’Donnell, C. J., Tofler, G. H., Benjamin, E. J., Fox, C. S., Lipinska, I., Nathan, D. M., Sullivan, L. M., D’Agostino, R. B., & Wilson, P. W. F. (2006) · Diabetes · doi:10.2337/diabetes.55.02.06.db05-1041 · Cited by 184
Gerstein, H. C., Thorpe, K. E., Wayne Taylor, D., & Brian Haynes, R. (2002) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(01)00325-4 · Cited by 169
Accuracy of veterans administration databases for a diagnosis of rheumatoid arthritis
Singh, J. A., Holmgren, A. R., & Noorbaloochi, S. (2004) · Arthritis Care & Research · doi:10.1002/art.20827 · Cited by 159
Interleukin-1–Receptor Antagonist in Type 2 Diabetes Mellitus
Mandrup-Poulsen, T., Seifert, B., & Donath, M. Y. (2007) · New England Journal of Medicine · doi:10.1056/nejmc071324 · Cited by 119
Checking the Cox Model with Cumulative Sums of Martingale-Based Residuals
Lin, D. Y., Wei, L. J., & Ying, Z. (1993) · Biometrika · doi:10.2307/2337177 · Cited by 103
O’Connor, P. J., Rush, W. A., Pronk, N. P., & Cherney, L. M. (1998) · PubMed · Cited by 98
Insulin Resistance as a Proinflammatory State: Mechanisms, Mediators, and Therapeutic Interventions
Garg, R., Tripathy, D., & Dandona, P. (2003) · Current Drug Targets · doi:10.2174/1389450033490920 · Cited by 95
Risk of Myocardial Infarction in Patients With Psoriasis
THIERS, B. H. (2007) · Yearbook of Dermatology and Dermatologic Surgery · doi:10.1016/s0093-3619(08)70383-6 · Cited by 64
Cited by
Inflammation, metaflammation and immunometabolic disorders
Hotamisligil, G. S. (2017) · Nature · doi:10.1038/nature21363 · Cited by 2,570
Inflammation in obesity, diabetes, and related disorders
Rohm, T. V., Meier, D. T., Olefsky, J. M., & Donath, M. Y. (2022) · Immunity · doi:10.1016/j.immuni.2021.12.013 · Cited by 2,066
The cellular and signaling networks linking the immune system and metabolism in disease
Osborn, O., & Olefsky, J. M. (2012) · Nature Medicine · doi:10.1038/nm.2627 · Cited by 1,551
Adapting to obesity with adipose tissue inflammation
Reilly, S. M., & Saltiel, A. R. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.90 · Cited by 1,204
COVID-19 and diabetes mellitus: from pathophysiology to clinical management
Lim, S., Bae, J. H., Kwon, H.-S., & Nauck, M. A. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00435-4 · Cited by 1,006
Metadata
- Authors
- Solomon, D. H.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2011-06-22
- Volume
- 305
- Issue
- 24
- Pages
- 2525
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2085667526
- Cited by
- 393
- References
- 38
- FWCI
- 22.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.